Search Results 221-230 of 7348 for infliximab

  1. https://www.mayoclinic.org/patient_consumer_drug.xml

    ... infliximab-axxq-intravenous-route/description/drg-20476981</loc><lastmod>2025-02-01T00:00:00-06:00</lastmod></url><url><loc>https://www.mayoclinic.org/drugs ...

  2. Ustekinumab-auub (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Cyclosporine; Dengue Tetravalent Vaccine, Live; Ebola Zaire Vaccine, Live; Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus ...

  3. Axitinib (oral route) - Mayo Clinic

    Axitinib is used together with other medicines (eg, avelumab, pembrolizumab) as first-line treatment of advanced renal cell carcinoma (RCC), a type of kidney ...

  4. Etanercept-ykro (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Baricitinib; Cholera Vaccine, Live; Cyclophosphamide; Dengue Tetravalent Vaccine, Live; Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live ...

  5. Tocilizumab In The Treatment Of Refractory Polymyositis And Dermatomyositis - Mayo Clinic

    8 week washout for infliximab or adalimumab; 2 week washout for etanercept; 1 week washout for anakinra. If an IS agent is continued, the dose must remain ...

  6. Drugs and Supplements that Start with R - Mayo Clinic

    Infliximab (intravenous route). Renflexis. Also known as. Infliximab-abda (intravenous route). Reno-30. Also known as. Diatrizoate (intravenous route). Reno-60.

  7. Natalizumab (intravenous route) - Side effects & uses - Mayo Clinic

    Infliximab; Vedolizumab. Other Interactions. Certain medicines should not be used at or around the time of eating food or eating certain types of food since ...

  8. A Study Of Vedolizumab In Children And Teenagers With Moderate To Severe Crohn's Disease (CD) - Mayo Clinic

    corticosteroids, immunomodulators (eg, AZA, 6-mercaptopurine, methotrexate), and/or TNF-α antagonist therapy (e.g., infliximab, adalimumab). This includes ...

  9. Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease - Mayo Clinic

    Maintenance monotherapy: infliximab (at least 8 every 8 weeks), golilumumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least ...

  10. A Study To Evaluate The Accuracy Of The Length-109 Probe Set Panel (A Genetic Test) In Predicting Response To Golimumab In Participants With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    biologic therapy targeted at tumor necrosis factor alpha (eg, infliximab, adalimumab, golimumab, etanercept, certolizumab);; natalizumab within 12 months of ...